- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07310264
Investigação sobre a Segurança de um Novo Agente (VT-5006) em Pessoas Com e Sem Doença de Parkinson
Um Estudo de Fase I, Randomizado, de Dose Única Ascendente, Dose Múltipla Ascendente, Duplamente Cego para Avaliar a Segurança, Tolerabilidade, Farmacocinética e Farmacodinâmica do AX-5006 (também conhecido como VT-5006) em Participantes Saudáveis e Participantes com Doença de Parkinson.
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD). The goal of this clinical trial is to learn if VT-5006 is safe and tolerable in healthy volunteers and in participants with PD. It has three Parts (A, B, and C).
Part A: Healthy volunteers aged 18-54 will attend a screening visit, take a single dose of VT-5006 or matching placebo after an overnight fast, stay in the clinic for three nights, and complete a follow-up visit. One group of participants in Part A will be asked to return to the clinic after approximately two weeks, take a single dose of VT-5006 or matching placebo after consuming a high-fat meal and stay in the clinic for another three nights.
Part B: Healthy volunteers aged 18-54 will attend a screening visit, take one dose of VT-5006 or matching placebo each day for seven days after fasting overnight, stay in the clinic for 10 nights, and complete a follow up visit.
Part C: Participants with PD aged 40-80 will attend a screening visit, take one dose of VT-5006 (high dose), VT-5006 (low dose), or matching placebo each day for 28 days, complete two overnight stays in the clinic, attend three clinic visits, one phone call and a follow up visit.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Part A will consist of five single ascending dose (SAD) cohorts, with 8 participants in each cohort. Participants will be randomized to receive either VT-5006 or placebo in a 6:2 ratio. One cohort of 8 participants will complete an additional clinic stay for the purpose of evaluating food effect (FE).
Part B will consist of two multiple ascending dose (MAD) cohorts, with 10 participants in each cohort. Participants will be randomized to receive either VT-5006 or placebo in an 8:2 ratio.
Part C will consist of a single cohort of approximately 24 (or up to 32) participants with PD, randomized to receive either VT-5006 (high dose), VT-5006 (low dose) or placebo over 28 days in a 9:9:6 ratio.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Leiden, Holanda
- Center for Human Drug Research
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Parts A and B enroll healthy volunteers; only key entry criteria for Part C are described below.
Inclusion Criteria:
- Diagnosed with PD confirmed by a neurologist within a maximum of 10 years (based of year of diagnosis) prior to screening
- Has current or history of GI motility dysfunction or persistent constipation
- Score of < 3 on the Modified Hoehn and Yahr Scale
- Is able to swallow multiple and large capsules without assistance or difficulty, in the opinion of the investigator
- Participants should be on a stable regimen of any prescribed (except levodopa/carbidopa, levodopa/benserazide or anticholinergic agents) or over-the-counter medications or supplements for at least 60 days prior to enrolment in the study. Participants should not change the dosage or frequency of these medications or supplements while in the study. If changes to medications or supplements are contemplated during the study, the Investigator should be contacted prior to any change.
- Has suitable venous access for blood sampling
Exclusion Criteria:
- Has a known allergy or hypersensitivity to any component of the formulation of VT-5006 or matching placebo, or history of severe allergy or anaphylaxis to a drug, food, or other exposure
- Participants taking levodopa/carbidopa or levodopa/benserazide must remain on a stable dose and regimen from at least 21 days prior to Day 1 visit to end of study (EOS) visit. Other treatments for PD symptoms may be allowed at the discretion of the medical monitor
- Has any clinically significant arrhythmia(s) on ECG; specifically, the participant's corrected QT interval (QTcf) (Fridericia's correction) is >450 ms for males or >470 ms for females
- Has clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy participants
- Has any of the following test results: a serum total bilirubin value >1.5 x upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value 2x ULN. As an exception, participants that present with elevated bilirubin in the absence of elevations in ALT or AST that fits the pattern of Gilbert's syndrome may be enrolled after discussion with the medical monitor if their conjugated bilirubin is not or slightly elevated and the level is considered to be not clinically significant.
- Any history of lumbar surgery for any reason (e.g. herniated disc) that in the opinion of the Investigator would interfere with or pose risks to a lumbar puncture procedure
- Other contraindications to having a lumbar puncture
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A SAD Active
Single Ascending Doses of VT-5006 |
Oral Capsules, Active
Outros nomes:
|
|
Comparador de Placebo: Part A SAD Placebo
Matched Placebo |
Oral Capsules, Matched Placebo |
|
Experimental: Part B MAD Active
Multiple ascending doses of VT-5006 |
Oral Capsules, Active
Outros nomes:
|
|
Comparador de Placebo: Part B MAD Placebo
Matched Placebo |
Oral Capsules, Matched Placebo |
|
Experimental: Part C Active Low Dose
Low dose VT-5006 |
Oral Capsules, Active
Outros nomes:
|
|
Experimental: Part C Active High Dose
High dose VT-5006 |
Oral Capsules, Active
Outros nomes:
|
|
Comparador de Placebo: Part C Placebo
Matched placebo |
Oral Capsules, Matched Placebo |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with treatment-related adverse events (AEs)
Prazo: Part A: Up to 8 days; Part B: Up to 15 days; Part C: Up to 35 days;
|
Incidence of treatment-emergent AEs (e.g. clinically significant electrocardiogram, vital signs and physical examination abnormalities; clinically significant changes on the Columbia-Suicide Severity Rating Scale [C-SSRS]). |
Part A: Up to 8 days; Part B: Up to 15 days; Part C: Up to 35 days;
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Plasma pharmacokinetic (PK) parameter: Cmax
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Maximum peak plasma concentration (Cmax) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameter: Tmax
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Time to Maximum Observed Concentration (Tmax) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameter: AUClast
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameters: AUCinf
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Area under the concentration-time curve extrapolated to infinity (AUCinf) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameter: t1/2
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Terminal-phase elimination half-life (t1/2) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameter: Apparent CL/F
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Apparent clearance (CL/F) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Plasma PK parameter: Apparent Vd/F
Prazo: Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
Apparent volume of distribution (Vd/F) |
Part A: predose, and up to 72 hours postdose; Part B: predose, and up to 37 hours postdose on Days 1 and 7; Part C: predose, and up to 10 hours postdose on Days 1 and 28
|
|
Food effect on plasma PK: Cmax
Prazo: Part A: predose and up to 72 hours postdose
|
Cmax following a high fat meal |
Part A: predose and up to 72 hours postdose
|
|
Food effect on plasma PK: Tmax
Prazo: Part A: predose and up to 72 hours postdose
|
Tmax following a high fat meal |
Part A: predose and up to 72 hours postdose
|
|
Food effect on plasma PK: AUC
Prazo: Part A: predose and up to 72 hours postdose
|
AUC following a high fat meal |
Part A: predose and up to 72 hours postdose
|
|
Urine PK parameter: CLr
Prazo: Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
Renal clearance rate (CLr) |
Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
|
Urine PK parameter: Cumulative amount excreted (urine)
Prazo: Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
Cumulative amount excreted in urine |
Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
|
Urine PK parameter: %Cumulative amount excreted
Prazo: Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
Percent cumulative amount excreted in urine |
Part A: Up to 72 hours postdose; Part B: Up to 24 hours postdose on Days 1 and 7; Part C: Up to 8 hours postdose on Days 1 and 28
|
|
Feces PK parameter: Observed concentration
Prazo: Part A: 0-72 hours postdose; Part B: 0-12 hours and 12-24 hours postdose on Days 1 and 7, and anytime postdose on Day 4; Part C: Anytime postdose on Days 8, 15, 22 and 28
|
Observed concentration in fecal samples (ng/mL) |
Part A: 0-72 hours postdose; Part B: 0-12 hours and 12-24 hours postdose on Days 1 and 7, and anytime postdose on Day 4; Part C: Anytime postdose on Days 8, 15, 22 and 28
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- VT-5006-101
- AXL-5006-101 (Outro identificador: Vertero Therapeutics)
- 2025-523254-14-00 (Ctis)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .